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REVIEW
Abstract: The progressive stiffening of the large arteries in humans that occurs during aging
constitutes a potential risk factor for increased cardiovascular morbidity and mortality, and is
accompanied by an elevation in systolic blood pressure and pulse pressure. While the underlying
basis for these changes remains to be fully elucidated, factors that are able to influence the
structure and composition of the extracellular matrix and the way it interacts with arterial
smooth muscle cells could profoundly affect the properties of the large arteries. Thus, while
age and sex represent important factors contributing to large artery stiffening, the variation in
growth-stimulating factors and those that modulate extracellular production and homeostasis
are also being increasingly recognized to play a key role in the process. Therefore, elucidating
the contribution that genetic variation makes to large artery stiffening could ultimately provide
the basis for clinical strategies designed to regulate the process for therapeutic benefit.
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Introduction
Large artery stiffness is a principal determinant of pulse pressure and can increase
the risk of cardiovascular morbidity and mortality via an elevation of systolic blood
pressure (leading to elevations in left ventricular afterload) and a reduction in diastolic
blood pressure altering coronary perfusion (Dzau and Safar 1988). Such stiffening
can occur via processes that involve changes in the overall dimensions of arteries
arising from medial hypertrophy and increased wall thickness – “geometry-dependent”
(Benetos, Laurent, et al 1993; Jaeckel and Simon 2003); or it can result from
perturbations in the amounts of arterial matrix, both elastic and extracellular, such
that the orderly arrangement of elastic fibers and lamenae is degraded over time and
an increase in collagenous material occurs – “geometry-independent” (Lakatta 1987;
Laurent et al 2005). Although a number of factors combine to determine increases in
large artery stiffening, a principal determinant is age; the central arteries stiffen
progressively over time while the peripheral muscular arteries do not appear to undergo
such profound structural changes (Benetos et al 2002). Indeed, by use of a variety of
assessment criteria, age-dependent increases in arterial stiffening have been described
in both healthy and diseased populations, predominantly occurring from the age of
10 years in both males and females (Laogun and Gosling 1982). These increases in
large artery stiffness, whether they occur within the aorta or carotid artery, do so in a
continuous and gradual manner (van der Heijden-Spek et al 2000), although there is
some indication that a more pronounced increase occurs from the age of 55 years
onwards (Nagai et al 1999). It is interesting that telomeric length, a heritable indicator
of biological aging, may also be indicative of vascular aging given that it appears to
inversely correlate with increased arterial stiffening (Jeanclos et al 2000; Benetos et
al 2001).
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Whereas large artery stiffening increases gradually with
aging independently of the occurrence of cardiovascular risk
factors or other associated conditions, a number of studies
clearly suggest that the superimposition of environmental
and genetic factors is also likely to be critical in the process.
Some of these environmental factors include nutritional
status, smoking, and aerobic capacity. Increasingly, the
influence of genetic factors is becoming better understood
in terms of how it may affect the epidemiology of large
artery stiffening. Studies carried out a decade ago in rat
models of salt-sensitive hypertension (Benetos et al 1995;
Levy et al 1997) and in human sodium-sensitive hyper-
tensives (Draaijer et al 1993) seem to indicate that
hemodynamic and humoral factors alone cannot fully
account for differences in mechanoelastic arterial properties
when compared with the situation in salt-resistant or
normotensive controls. This suggests a major influence of
predisposing genetic factors on arterial mechanical
properties. Indeed, some studies suggest that the total genetic
heritability of aortic stiffening determinants, which are
independent of the influence of blood pressure, heart rate,
height, and age, may make a substantial contribution,
perhaps as high as 30%–40% (Snieder et al 2000).
Furthermore, the results of genome-wide linkage analyses
of pulse pressure indicate that while some overlap may exist
between genetic components that underlie blood pressure
phenotypes (Atwood et al 2001), there is also likely to be a
distinct set of genes that contribute to the modulation of
arterial stiffness (Camp et al 2003; DeStefano et al 2004).
In this regard, a number of polymorphisms in various genes
have been found to associate with increased arterial
stiffening, thereby implicating these genes in this process.
In this review, the current knowledge about these genetic
factors is discussed, as is the potential molecular basis that
underlies their involvement in arterial stiffening, particularly
as it relates to the growth of arteries, the structure and
remodeling of the extracellular matrix, and the interactions
that occur between the extracellular matrix and the cellular
components of the artery.
Nonmatrix gene polymorphisms
The renin–angiotensin system
Local hormonal factors that may play a pressure-
independent role in the arterial wall via a modification of
cellular growth or by influencing the extracellular matrix
include angiotensin II acting via the angiotensin II type 1
receptor (AT1-R). Animal studies using both Wistar Kyoto
and spontaneously hypertensive rats (SHR) have
demonstrated that inhibition of angiotensin-converting
enzyme (ACE) activity can reduce stiffness within the
carotid artery independently of transmural pressure, both
when the drug was administered locally (Levy et al 1990)
and after acute oral administration (Benetos, Pannier, et al
1993). In both studies, changes in stiffness were seen even
in the absence of significantly lowered systemic blood
pressure. Experimentation using two-kidney, one-clip
Goldblatt hypertensive rats, and SHR indicated that the
beneficial effect of ACE inhibition may arise via effects on
vascular smooth muscle cell hypertrophy (Levy et al 1988,
1993) or collagen accumulation (Albaladejo et al 1994;
Benetos et al 1997).
While in humans the relationship between ACE
inhibition and arterial stiffness is likely to be more complex,
it has been demonstrated that long-term administration of
ACE inhibitors to individuals with essential hypertension
significantly reduces arterial stiffness within the brachial,
radial, abdominal, and carotid arteries (Asmar et al 1988;
De Luca et al 1993; Kool et al 1995). Such findings are
consistent with the observations of elevated levels of ACE
in humans with increased thickness of the carotid wall
(Bonithon-Kopp et al 1994). Both ACE inhibition and
AT1-R blockade, in either acute or long-term treatment, can
reduce the stiffness of muscular arteries independent of
changes in mean blood pressure (Topouchian et al 1998,
1999; Benetos et al 2000). In view of these observations, it
has been of interest to ascertain whether genetic poly-
morphism within the ACE and AT1-R genes may be
associated with alterations in arterial stiffness. For example,
it has been shown that specific polymorphisms within the
AT1-R and ACE genes within hypertensive individuals do
appear to be involved in the regulation of aortic stiffness.
Specifically, in the study by Benetos, Gautier, et al (1996),
in which arterial stiffness was assessed by measuring aortic
pulse wave velocity (PWV), the AT1-R A1166C polymorphism
was the second most important determinant of aortic stiffness
in hypertensives, accounting for 11.6% of PWV variance,
an effect that appeared to be co-dominant. Although a strong
association between the AT1-R A
1166C genotype and PWV
was observed in both young and old hypertensives, the effect
was more pronounced in the older individuals, suggesting
that this polymorphism may amplify the effects of age on
arterial stiffness. Some studies have provided data consistent
with the C allele influencing arterial stiffness, for example
the demonstration that ACE inhibition with perindoprilVascular Health and Risk Management 2005:1(4) 335
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reduced PWV threefold in carriers of the C allele as
compared with individuals homozygous for the A allele
(Benetos, Cambien, et al 1996). Interestingly, the presence
of the C allele has been associated with increased
vasoconstriction of both the coronary arteries (Amant et al
1997) and the internal mammary artery (Henrion et al 1998).
More evidence that the AT1-R A
1166C polymorphism is
likely to be a key determinant in the process of arterial
stiffening has been provided in a recent study in which an
additional cohort of individuals was also found to exhibit
association between this polymorphism and arterial
stiffening, although in this study (Gardier et al 2004) it was
the A allele that was associated with such increased
stiffening. Additional involvement of the AT1-R gene in the
process of arterial stiffening has been provided by Lajemi,
Labat, et al (2001), demonstrating an age-related association
between the AT1-R A153G polymorphism and aortic stiffness.
In the study by Benetos, Gautier, et al (1996), the ACE I/D
polymorphism showed an association with aortic stiffness,
albeit at a lower level, accounting for less than 2% of the
PWV. This polymorphism has also been found to be
associated with aortic and carotid artery stiffening in a group
of 137 Japanese individuals with type 2 diabetes (Taniwaki
et al 1999). In addition to these data is the study by Mattace-
Raso et al (2004), demonstrating an association between
this polymorphism and common carotid artery stiffness in
individuals younger than 70 years. Some studies also
indicate that the ability of this polymorphism either to
modulate increases in pulse pressure (Safar et al 2004) or
to influence diastolic blood pressure (Rudnichi et al 2004)
is likely to be dependent on age and sex, with males being
more susceptible to these outcomes. It should also be noted
that there may be additional complexity to the relationship
between the ACE I/D polymorphism and the AT1-R A
1166C
polymorphism and modulation of arterial stiffness, as there
is evidence that in some population cohorts these
polymorphisms do not strongly affect the stiffness of either
the carotid or radial arteries (Girerd et al 1998).
A key factor that regulates the amount of angiotensin II
is its generation from angiotensinogen. Polymorphisms have
been detected within the human angiotensinogen gene,
which appear to correlate with plasma concentrations of
angiotensinogen, specifically the variant M235T, which
arises from a thymidine-to-cytosine transition at
nucleotide position 704 and causes substitution of a
methionine for a threonine at residue 235 in the mature
angiotensinogen peptide (Jeunemaitre et al 1992). In some
studies the T235 allele has been found to be associated with
higher plasma concentrations of angiotensinogen in
individuals homozygous for this allele (Bloem et al 1997),
and it has also been associated with hypertension (Caulfield
et al 1995). This polymorphism has also been found to
associate with arterial structure, with hypertensive
individuals homozygous for the T235 allele exhibiting a
higher amount of carotid intimamedia thickness (Bozec et
al 2003). More importantly, this polymorphism has also very
recently been shown to be associated with arterial stiffness.
In a study by Bozec et al (2004) in which 98 untreated
hypertensive individuals were assessed for arterial stiffness,
those who were homozygous for the T235 allele had, on
average, increased carotid artery stiffness compared with
the T/M235 heterozygotes and the M235 homozygotes.
Such data provide further evidence that perturbation within
a number of the genes encoding for components of the renin–
angiotensin system is likely to play a key role in the process
of large artery stiffening.
Aldosterone synthase
Aldosterone is a mineralocorticoid hormone which is in-
volved in the regulation of blood pressure through its effects
on sodium balance and intravascular volume (White 1994).
Experimental studies have demonstrated that aldosterone
may be capable of playing a prominent role in regulating
the structure of large arteries. For example, aldosterone
receptors occur within the large arteries, particularly the
aorta (Lombes et al 1992). Endogenous vascular synthesis
of aldosterone can also occur (Takeda et al 1995). It has
also been demonstrated that aldosterone can increase the
expression of both cardiac and vascular collagens (Robert
et al 1994; Sun et al 1997). It has been more recently dem-
onstrated that aldosterone can amplify the proliferative
effects of angiotensin II on vascular smooth muscle cells
via an increase in expression of the AT1-R (Xiao et al 2004).
Synthesis of aldosterone occurs in the adrenal cortex
from deoxycorticosterone, via the action of a mitochondrial
cytochrome P450 enzyme aldosterone synthase (CYP11B2),
the gene for which can be regulated by angiotensin II (White
1994). Interestingly, polymorphisms within the CYP11B2
gene that may influence its activity have also been found. A
common polymorphism within the promoter region has been
demonstrated to influence binding of the transcriptional
regulatory protein SF-1 (White and Slutsker 1995). This
C/T polymorphism (-344C/T), occurring 344 nucleotides
upstream of the translational start site of the CYP11B2Vascular Health and Risk Management 2005:1(4) 336
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protein, is within a region in which the steroidogenic
transcription factor SF-1 binding occurs, and studies have
found that plasma aldosterone levels or urinary aldosterone
excretion can vary according to the -344 genotype
(Hautanena et al 1998; Pojoga et al 1998). This poly-
morphism has also been found to be associated with arterial
stiffening in a study in which 216 hypertensive individuals
of European origin were assessed for plasma levels of renin
and aldosterone, blood pressure, and PWV as a measure of
arterial stiffness (Pojoga et al 1998). The presence of the
-344C allele was associated with elevated levels of plasma
aldosterone, with the CC homozygous individuals having
on average the highest levels, and the TT homozygotes
having the lowest level. Individuals carrying the C allele
also exhibited a higher degree of arterial stiffening as
assessed from measurements of PWV. Consistent with such
polymorphisms influencing arterial stiffness via perturba-
tions in aldosterone levels have been the findings that an
increase in carotid artery stiffness in response to long-term
aldosterone administration to Sprague-Dawley rats can be
ameliorated by treatment with the mineralocorticoid
antagonist eplerenone (Lacolley et al 2002) and that salt-
dependent increases in stiffness in the mesenteric vessels
of spontaneously hypertensive stroke-prone rats could also
be blunted by treatment with this aldosterone antagonist
(Endemann et al 2004).
Moreover, there is evidence demonstrating that gene–
gene interaction between components of the rennin–
angiotensin–aldosterone system act to modulate large artery
properties. For example, in a study of 756 Belgian
individuals ranging in age from 12–79 years, a single-gene
effect was observed to occur for the ACE I/D polymorphism
on compliance of the common carotid artery, with the D
allele being associated with decreased compliance
(Balkestein et al 2001). In multigenetic analysis, it was seen
that the influence of the ACE D allele depended on both
“vascular territory” and genetic background, such that the
presence of the aldosterone -344T allele appeared necessary
to bring about the negative association of the ACE D allele
on distensibility of the common carotid artery (Balkestein
et al 2001). Although such an interaction occurred at the
level of the common carotid artery, it did not appear to
influence properties of the femoral artery. Rather, in the
latter, ACE DD homozygotes, when additionally homozy-
gous for the α-adducin Gly460 allele, had lower cross-
sectional compliance and lower distensibility (Balkestein
et al 2001).
Guanine nucleotide regulatory proteins
(G-proteins)
G-proteins are key components of a plethora of intracellular
signaling cascades, relaying signals from more than 1000
receptors to a diversity of intracellular effector molecules,
including enzymes and ion channels (Farfel et al 1999). The
structural features of the G-protein are an α-subunit bound
loosely to a tightly associated dimer consisting of a β- and
a γ-subunit, each subunit being the product of a different
gene. Diversity of G-protein composition is generated via
the number of different genes that encode for these subunits,
with 16 α-subunit genes, 6 β-subunit genes, and 12 γ-subunit
genes (Farfel et al 1999). It is known that mutations within
these trimeric proteins are involved in a number of disease
states, including hypertension. Specifically, a common
C-to-T polymorphism in exon 10 (C825T) of the β3 subunit
whereby the T allele is associated with a splice variant
(GNB3-s) in which the nucleotides 498–620 of exon 9 are
deleted in-frame, thereby truncating the β3 protein by 41
amino acids, has been demonstrated to be capable of
significantly enhancing signaling when in a trimeric complex
with Gαi2 and Gγ5 (Siffert et al 1998). Interestingly, the
825T allele has been associated with hypertension
(Benjafield et al 1998; Schunkert et al 1998; Siffert et al
1998; Dong et al 1999) and higher blood pressure
(Benjafield et al 1998; Schunkert et al 1998; Hengstenberg
et al 2001). Moreover, the potential for this polymorphism
to influence arterial structure has been demonstrated by the
finding that in a French cohort of 306 individuals with no
history of cardiovascular disease, a significant association
existed between the 825T allele and radial artery
hypertrophy, independent of age, blood pressure, sex, and
body mass index (Hanon et al 2002). This polymorphism
has been recently found to be associated with arterial
stiffness, as measured by PWV and augmentation index
(Nürnberger et al 2004). Specifically, this study compared
a group of young healthy males with and without the 825T
allele under resting conditions, finding that carriers of this
allele exhibited a significantly higher PWV and
augmentation index than individuals with the CC genotype.
Although the underlying mechanistic basis linking such a
polymorphism to arterial stiffening remains to be fully
elucidated, it may relate to altered vascular remodeling
events arising from aberrant vascular smooth muscle cell
proliferation in response to enhanced Na
+/H+ exchanger
activity (Siffert 2000).Vascular Health and Risk Management 2005:1(4) 337
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Nitric oxide synthase
In addition to factors that can influence the growth of
vascular smooth muscle cells or the expression of
extracellular matrix proteins within the arterial wall, a degree
of functional regulation of smooth muscle tone by circulating
and locally produced vasoactive factors may also influence
arterial stiffness. One such factor, nitric oxide, is synthesized
from L-arginine in vascular endothelial cells by the action
of the enzyme endothelial nitric oxide synthase (eNOS) and
has a profound effect on both vascular tone and blood
pressure (Palmer et al 1987; Rees et al 1989). In this regard
it has been demonstrated that both exogenous and
endogenous eNOS inhibitors, which decrease basal
endothelial cell eNOS, can cause an increase in carotid artery
intimamedia thickness (Lacolley et al 1998; Wilkinson et al
2002). Within the human eNOS gene, a polymorphic
transversion of a G-to-T nucleotide at position 894 (G894T)
within exon 7 results in a substitution of Glu by Asp at amino
acid residue 298 (Glu298Asp) (Marsden et al 1993). This
polymorphism has been shown to influence vascular
responsiveness to vasoconstricting hormones, with the 894T
allele being associated with an enhancement of the
hemodynamic response to phenylephrine in a cohort of
individuals undergoing cardiac pulmonary bypass surgery
(Philip et al 1999). Interestingly, a relationship between this
polymorphism and blood pressure level was found to occur,
with the T allele being associated with lower blood pressure
in a young adult cohort aged 19–38 years in the Bogalusa
Heart Study (Chen et al 2001). In a recent study examining
the independent effect of the G894T eNOS polymorphism
on arterial stiffness in 118 African Americans and 285 white
young adults (aged 25–37 years), the T allele was associated
with lower systolic blood pressure and a lower degree of
carotid artery stiffening within the African American cohort
(Chen et al 2004), after adjusting for insulin, heart rate, and
mean arterial pressure. The genotype effect was not
significant within the white male cohort, an observation
consistent with a previous study utilizing a French cohort
in which the T allele was not found to be significantly
associated with PWV (Lacolley et al 1998). It appears likely
that the eNOS gene may be one of the key underlying factors
that contribute to the observed ethnic differences in both
hypertension and arterial stiffness. The mechanistic basis
for how the G894T eNOS polymorphism could be linked
with effects on arterial stiffness remains unclear, but is likely
to relate to the ability of nitric oxide not only to be involved
in the maintenance of vascular tone but also to exert an effect
on arterial mechanical properties via inhibition of vascular
smooth muscle cell proliferation (Garg and Hassid 1989;
Jeremy et al 1999). At this stage, the relationship between
the G894T eNOS polymorphism and eNOS enzyme activity
and subsequent nitric oxide production is yet to be clarified,
with the polymorphism having no significant effect on eNOS
activity in a study in which this parameter was tested
(Kamitani et al 1998). Another possibility is that the G894T
polymorphism either is in strong linkage disequilibrium with
another, as yet unidentified, eNOS polymorphism(s) that
has an effect on enzyme activity or is linked with another
gene that influences arterial stiffness.
Endothelin and endothelin receptors
Endothelins -1, -2, and -3 are peptides of 21 amino acids,
produced from different genes in a diverse array of cells,
with endothelin-1 (ET-1) – the only member of the family
to be expressed in endothelial cells and vascular smooth
muscle cells (Levin 1995) – being a potent paracrine
vasoconstrictor that can modulate vasomotor tone, cell
proliferation, and vascular remodeling (Komuro et al 1988;
Levin 1995). These peptides exert their biological responses
by binding to two types of receptors (ETAR and ETBR),
which are G-protein linked and range in size from 45 kDa
to 50 kDa in various cells and tissues, including vascular
smooth muscle cells and endothelial cells (Sakurai et al
1990; Seo et al 1994). Although this is somewhat
controversial, a relationship may exist between the
expression of endothelin/endothelin receptors and
hypertension, with some studies showing overexpression
of both ET-1 and its ETAR genes in arteries of hypertensive
patients (Hasegawa et al 1994; Schiffrin et al 1997) and
others finding elevated ET-1 levels in some hypertensive
animal models (Larivière, Day, et al 1993; Larivière,
Thibault, et al 1993) and in some patients with hypertension
(Yokokawa et al 1991). A number of polymorphisms have
also been identified within both the ET-1 and ETR genes
that have shown associations with either hypertension or
elevated pulse pressure (Nicaud et al 1999; Jin et al 2003).
As well, an association has been found between specific
ETR polymorphisms and arterial stiffness. In a study by
Lajemi, Gautier, et al (2001) 528 untreated hypertensive
individuals of European origin (314 men, 214 women) were
assessed for aortic stiffness using PWV measurement and
association with the ETAR – 231 A/G and +1363 C/T
polymorphisms, the ETBR +30 G/A polymorphism, and the
ET-1 138 I/D polymorphism. In women, these analysesVascular Health and Risk Management 2005:1(4) 338
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showed that the age-adjusted PWV was associated with both
the ETAR –231 A/G polymorphism and the ETBR +30 G/A
polymorphism, with the –231 G and +30 G alleles being
associated in a co-dominant manner with higher PWV, both
alleles being significant independent determinants of PWV.
In men, no association was seen for any of these
polymorphisms and PWV, although the presence of the
ETBR 30A allele was associated with higher levels of radial
artery wall cross-sectional area (Lajemi, Gautier, et al 2001).
The mechanistic basis for such sex-specific association
between the ETAR polymorphisms and arterial stiffening
has yet to be elucidated.
Extracellular matrix gene and
matrix metalloproteinase gene
polymorphisms
Matrix homeostasis is also a critical determinant of the
mechanical properties of the blood vessel, and the
mechanisms whereby matrix proteins are regulated in their
accumulation and deposition are therefore likely to play key
roles in the process of arterial stiffening (Safar et al 2003).
In view of the information pertaining to polymorphism in
the genes described above, it is critical to understand the
extent to which polymorphism within extracellular matrix
genes themselves and genes that encode for the proteins
that regulate matrix homeostasis (the matrix metallo-
proteinases [MMPs]) plays a role in relation to the process
of arterial stiffening. Evidence is emerging to indicate the
contribution of genetic variation to both the composition
and accumulation of the arterial extracellular matrix and to
the activity of specific MMPs (Ye 2000).
Elastin and fibrillin-1
Major determinants of the arterial distensibility of large
blood vessels include desmin (Lacolley et al 2001) and
elastin. The latter, a highly insoluble extracellular matrix
protein synthesized as a soluble precursor, tropoelastin, by
vascular cells (including smooth muscle cells), is the
principal component of elastic fibers from the arterial media
(Wolinsky and Glagov 1967). Interaction between the elastic
fibers and vascular proteoglycans may also influence arterial
geometric and elastic properties (Germain et al 2003).
Although no studies have yet been carried out to assess the
potential association of polymorphisms within the desmin
gene and arterial stiffness, a number of polymorphisms
have been identified within the elastin gene. One of these,
an A-to-G substitution resulting in a serine-to-glycine
replacement at amino acid 422 in the elastin protein, has
been demonstrated to be associated with carotid artery
distensibility, independent of age and blood pressure (Hanon
et al 2001).
Interestingly, recent genotype-phenotype studies have
revealed a potential link between polymorphisms within the
fibrillin-1 gene and aortic stiffness and coronary artery
disease severity (Medley et al 2002). Fibrillin-1 is the
principal constituent of 10-nm microfibrils and functions
as a scaffold for the deposition of tropoelastin, thereby
participating in both load-bearing and anchoring within the
artery. In Marfan syndrome, in which aortic stiffening and
elevated pulse pressure are the primary determinant of aortic
root dilation (Jondeau et al 1999), mutations in the fibrillin-1
gene leading to abnormalities in elastic fibers are known to
occur (Tsipouras et al 1992). In addition, within the fibrillin-1
gene, a polymorphic (variable) tandem nucleotide repeat
(VNTR) sequence, TAAAA, found within intron 28, has
been shown to be associated with elevated arterial pulse
pressure in men older than 50 years (Powell et al 1997).
More recently, this polymorphism has been found to
modulate large artery stiffness and pulse pressure within a
group of 145 individuals with moderate-severity coronary
artery disease (Medley et al 2002). Moreover, individuals
heterozygous for fibrillin-1 alleles in which the number of
TAAAA repeats was 2 and 3 (2–3 genotype) had stiffer large
arteries and higher pulse pressure than other genotypes for
this VNTR. Although the precise molecular mechanism
linking this intronic polymorphism to large artery stiffening
has yet to be elucidated, it may relate to an effect on gene
expression or occur via an influence on RNA splicing, as
the VNTR is located near the 3´ splicing boundary for exon
28 of the fibrillin-1 gene (Pereira et al 1993).
Type I collagen
Collagen is a primary constituent of extracellular matrix
and is abundant in bone, connective tissues, and the arterial
wall (Bedalov et al 1994). There is evidence to suggest an
interplay between the levels of elastin and collagen and the
mechanical properties of arteries with regard to stiffness
(Lakatta 1987; Laurent et al 2005). Polymorphism has been
shown to exist in the gene encoding for type I collagen,
which appears to be associated with arterial stiffness (Brull
et al 2001). This polymorphism (2046G/T) is located within
the promoter region of the collagen type I-α1 gene
(COL1A1) at the first base of a consensus site for the binding
of the transcription factor Sp1 and has previously been
shown to be associated with reduced bone density andVascular Health and Risk Management 2005:1(4) 339
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osteoporotic fracture (Grant et al 1996). In a study of 489
Northern Irish individuals (251 men and 238 women) the
T allele was associated with a higher aortic PWV,
independent of age, sex, and mean arterial pressure (Brull
et al 2001). Presumably, this polymorphism alters Sp1
binding and therefore affects transcription rates of the
COL1A1 gene, suggesting that altered collagen deposition
is directly related to the effects on arterial stiffening.
Matrix metalloproteinase-3 (MMP-3)
With regard to matrix homeostasis, MMP-3 (stromelysin-1)
is likely to be a critical regulator of arterial stiffness, given
its wide range of substrates that include most major matrix
components within arteries, such as the fibronectins,
collagens, gelatins, laminins, elastin, and various
proteoglycans (Wilhelm et al 1987). In addition, MMP-3 is
capable of activating other MMPs, such as collagenases
(Milner et al 2001), matrilysin (Imai et al 1995), and
gelatinase B (Dreier et al 2004). The level of MMP-3 is
regulated primarily by its gene transcription, and its
promoter is known to contain sequences that mediate
induction by various stimuli, including growth factors and
cytokines such as platelet-derived growth factor (Kanaki et
al 2002) and interleukin-12 (Monteleone et al 1999), and
suppression by agents such as dexamethasone (Hoshino et
al 2001). A common polymorphism has been found within
the MMP-3 promoter, giving rise to one allele that has a run
of six adenosines (6A) and another having a run of five
adenosines (5A) at nucleotide position –1171 relative to the
transcriptional start site (Ye et al 1995). The ability of this
polymorphism to influence expression of MMP-3 via effects
on transcription factor binding within the MMP-3 promoter
has been demonstrated from cell culture experiments, in
which the 5A allele has a higher promoter activity (Ye et al
1996). Moreover, this allele has been associated with acute
coronary events (Terashima et al 1999) and aortic aneurysms
(Yoon et al 1999), most likely via an increase in matrix
proteolysis. Conversely, the 6A allele has been found to be
associated with carotid intimamedia thickening (Gnasso et
al 2000; Rauramaa et al 2000), presumably via a mechanism
arising from an increase in matrix accumulation. The
relationship between MMP-3 allelic variation and age-
related large artery stiffening appears complex, with a
recent study demonstrating that both the 5A/5A and
6A/6A homozygotes are associated with age-related
aortic stiffening, as compared with the 5A/6A hetero-
zygotes exhibiting delayed large artery stiffening
(Medley et al 2003), thereby implying that either high
(5A/5A) or low (6A/6A) MMP-3 activity has an adverse
effect on the outcome over time on aortic stiffening. In the
situation of high MMP-3 activity, the mechanism underlying
the adverse increase in aortic stiffening may arise from the
augmented degradation of elastin leading to dilatation of
the vessel lumen and a subsequent increase in stiffness as
the elastin is replaced with stiffer collagen (O’Rourke 1995).
Subsequently, adverse effects regarding aneurysmal
formation could occur via the thinning of the atherosclerotic
vessel wall as collagen is then degraded by high MMP-3
activity, either directly or via its activation of other
collagenases (Carrell et al 2002). Alternatively, plaque
instability could occur via a similar degradation mechanism
leading to weakening of the fibrous cap in the advanced
atherosclerotic lesion (Terashima et al 1999; Nojiri et al
2003).
Matrix metalloproteinase-9 (MMP-9)
More recently, a potential involvement of MMP-9
polymorphisms on large artery stiffening has also been
reported. MMP-9, otherwise known as gelatinase B, is a
92 kDa type IV collagenase, which has been shown to be
highly expressed in the rupture-prone regions of human
atherosclerotic plaques (Galis et al 1994). As its name
suggests, it is particularly active at degrading gelatins, but
its substrate specificity is sufficiently broad to render it
capable of also degrading type IV collagen, a primary
substituent of the basement membrane that underlies the
endothelium and is found enveloping smooth muscle cells
(Birkedal-Hansen et al 1993). The expression of MMP-9 is
controlled in large part at the level of its gene transcription,
and it has been shown that factors such as interleukin-1
(Huhtala et al 1991), platelet-derived growth factor, tumor
necrosis factor-α (Fabunmi et al 1996), and epidermal
growth factor (Kondapaka et al 1997) can influence the
expression of MMP-9 via stimulation of its promoter region.
In this regard it has been shown that several cis-acting
elements in the MMP-9 promoter are critical in the
regulation of its transcription, including two AP-1 sites
bound by c-fos and c-jun transcription factors, a PEA3 motif
mediating regulation by the ETS transcription factor, and a
potential binding site for nuclear factor-κB (Huhtala et al
1991; Gum et al 1996). Additionally, sites mediating
transcriptional repression of the MMP-9 gene have been
identified within its promoter (Zhang et al 1999). Within
this 9-bp sequence a C-to-T polymorphism exists
(GCGCAC/TGCC), such that repression is minimal when
the T substitution (C1562T) occurs, as shown from transientVascular Health and Risk Management 2005:1(4) 340
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transfection experiments in cultured macrophages (Zhang
et al 1999). It has also been shown that individuals of the T/
T genotype tend to have a higher serum level of MMP-9
than those of either the C/T or C/C genotype (Blankenberg
et al 2003); furthermore, in a sample of 374 individuals from
France for whom coronary angiographic data were available,
there was a significant association between this
polymorphism and the severity of coronary atherosclerosis
as assessed by the number of coronary arteries that had a
stenosis > 50% (Zhang et al 1999). Using this criterion, the
number of patients with triple-vessel disease was higher in
the T/T and C/T genotypes than in the C/C genotypes.
Interestingly, this polymorphism has recently been shown
to associate with large artery stiffness in a group of
individuals with angiographically defined coronary artery
disease. Specifically, individuals carrying the T allele (either
T/T or C/T genotype) had stiffer large arteries (higher input
and characteristic impedance) and higher carotid pulse and
systolic blood pressure than individuals with the C/C
genotype (Medley et al 2004). Such a relationship remained
significant after age, sex, mean arterial pressure, total
cholesterol, low-density lipoprotein cholesterol, and
triglycerides were considered as covariates.
Moreover, in a subsample of eight aortic tissues from a
separate population of cardiac transplant patients, MMP-9
gene expression was found to be fivefold higher in T allele
carriers than in individuals with the C/C genotype (Medley
et al 2004); within these samples there was a trend towards
increased total MMP-9 protein in the T allele carriers, and
MMP-9 activity was significantly higher in this group. The
mechanism linking increased MMP-9 expression to large
artery stiffening could potentially occur via processes
involving vascular remodeling events. In this regard it is
interesting that in MMP-9-deficient mice, arterial
geometrical remodeling within the carotid artery has been
observed to be impaired subsequent to flow cessation (Galis
et al 2002), an effect most likely exerted through a
modulation of collagen metabolism and organization. A
relationship between MMP-9 expression and large artery
stiffening has also been seen in Marfan syndrome (Segura
et al 1998).
Conclusions
It has become increasingly recognized that the stiffening of
large arteries, a critical independent predictor of cardio-
vascular risk, is likely to be profoundly influenced by
variation within a diverse array of genes, the proteins for
which are involved in the modulation of arterial growth and
extracellular matrix properties. An expanding array of
genetic polymorphisms has been identified to associate with
arterial stiffness. This “candidate gene” approach has yielded
significant information about the identity of various genes
that are likely to be involved in human arterial stiffening,
and for some of these polymorphisms the mechanistic link
to this process has been suggested from structure-function
studies and supported by studies in appropriate animal
models. However, limitations to some of the studies must
be acknowledged, particularly where the mechanistic link
between the identified polymorphism(s) and the process of
arterial stiffening remains to be elucidated or in cases for
which specific polymorphisms have not been consistently
associated with arterial stiffness between different
population groups. In this regard, the use of complementary
approaches such as gene array profiling between individuals
with increased arterial stiffening as compared with
individuals with more distensible arteries has the potential
to discern genes in which polymorphisms result in
perturbations in protein expression, rather than direct effects
on protein function. The applicability of such an approach
has already been shown in a study in which a diverse set of
genes, including those involved in cellular signaling and
the mechanical regulation of vascular structure, were seen
to be differentially expressed in aortas with increased
stiffness (Durier et al 2003). The situation is likely to be
even more complex when the influence of linkage
disequilibrium and the combination of various poly-
morphisms, or haplotypes, is additionally considered. This
has been shown by studies indicating that when
combinatorial arrays of specific polymorphisms, either from
the same gene or between different genes, are used to
evaluate relationships to arterial stiffening, associations exist
that either were not evident or were less apparent when
considering one polymorphism alone (Balkestein et al 2001;
Mourad et al 2002). Clearly, future research in which there
is an integration of genetic, molecular, biochemical, clinical,
and epidemiological studies (as similarly advocated by
Staessen et al [2003]) to elucidate the genetic and
environmental factors that interact to cause human
hypertension should contribute significantly to a greater
understanding of the heritable factors that act to modulate
arterial stiffness. Ultimately, the clarification of these genetic
influences will allow for the targeting of key factors for
therapeutic benefit, particularly in individuals with either
increased or premature arterial stiffening.Vascular Health and Risk Management 2005:1(4) 341
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